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ABSTRACT 
 
Objective: To determine, “Does treatment with amantadine improve the rate of cognitive 
function in patients with Traumatic Brain Injury?” 
 
Study Design:  Review of three English language randomized controlled trials from 1999-2012 
 
Data Sources:  Three randomized, placebo-controlled, double blind crossover trials comparing 
amantadine to placebo were found using Pub-Med and Cochrane Databases. 
 
Outcomes Measured: The trials measured the effects of amantadine on command-following, 
object recognition, functional object use, intelligible verbalization, reliable yes-or-no 
communication, sustained attention, orientation, attention, memory, executive flexibility, and 
behavior and used the following assessment tools: Neurobehavioral Rating Scale and DRS 
(Disability Rating Scale). 
 
Results: Two studies demonstrated an improvement in eye opening, verbalization, motor 
response, cognitive understanding of feeding, dressing, and grooming; degree of assistance and 
supervision required; and employability at higher rates than the placebo.  One study did not 
indicate an increase of rate in improvement of cognitive function when comparing amantadine to 
placebo. 
 
Conclusion:  Based on two of the trials, treatment with amantadine does increase the rate of 
improvement of cognitive function in patients suffering from Traumatic Brain Injury.  One trial 
did not show an increase in rate of improvement, but small sample size discounted its validity. 
 
Key Words: Traumatic Brain Injury, Cognitive Function, Amantadine 
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Introduction 
Each year, severe traumatic brain injury contributes to a significant number of deaths and 
cases of permanent disability, as well as economic and familial consequences.2  TBI is the most 
common cause of death and disability in persons aged 15-30 and accounts for approximately 
one-third of all injury related deaths in the United States.1,2   The direct and indirect costs of TBI 
in the US have been estimated to be $48.3 billion annually.5  Survival costs account for $31.7 
billion and fatal brain injuries cost another $16.6 billion.5 
 Physical effects of traumatic brain injury can range from minimal symptoms like 
headaches, nausea, and dizziness to more severe consequences, such as decreased consciousness 
and cognitive function, vegetative states, and death.2,3,4   The severity of internal or external brain 
damage correlates to the amount of cognitive dysfunction.  The higher the severity of trauma to 
the skull/brain, the more severe the dysfunction will be, thereafter.  High-speed motor vehicle 
collisions cause 50% of traumatic brain injuries in the United States and tend to have the most 
detrimental effects.3    
 For severe TBIs, it is not known for sure how long a particular patient will take to regain 
lost cognitive function or to what degree that patient will heal.  A majority of healing occurs 
spontaneously and shortly after injury.4  There are off-label neuropharmicological therapies that 
attempt to increase consciousness and arrousability by tampering with dopaminergic and 
noradrenergic receptors, but the exact mechanism by which these medications work is not fully 
understood and effects are generally temporary.3 
 There is no current cure for Traumatic Brain Injury.2,3,4   Methods of pharmacological 
treatment are aimed at control of systemic physiological effects of TBI.3 Diuretics are used to 
decrease the amount of third-spacing as well as intracranial pressures.  Beta-blockers, ACEi and 
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ARBS are used to regulate blood pressure.  Medications to prevent seizures and control pain are 
also utilized, but stabilizing a TBI patient with these pharmacological agents does not improve 
the amount of cognitive damage initially sustained.  Currently the main methods of treatment of 
long-term cognitive damage are physical, speech, and occupational therapies.3  
Typically in the case of severe traumatic brain injury, such as those sustained in a motor 
vehicle collision, the mechanism is diffuse axonal injury (DAI).3  DAI involves a widespread 
damage to axons in the brain and is highly associated with a reduction of dopamine availability.3  
Amantadine is a medication that causes increased release of dopamine from neurons in the brain 
and delay of cellular uptake.3  It is known for its use as an antiparkinsonian agent and as an 
antiviral in treatment of influenza.3  Currently it is a topic for research in the area of traumatic 
brain injury, and is the focus of this systematic review. 
Objective 
The objective of this selective EBM review is to determine “Does treatment with 
Amantadine increase the rate of improvement of cognitive function in patients suffering TBI?”  
Previous studies have showed the benefits of using dopamine agonists in treatment of cognitive 
dysfunction; therefore, it is suggested that amantadine will have a positive impact on the rate of 
cognitive recovery in patients with TBI. 
Methods 
An online search was done to locate randomized control trials evaluating the use of 
amantadine in patients suffering TBI.  Articles used included male and female patients above the 
age of 16 with TBI and excluded those with previous chronic disease or cognitive disability.  50 
– 200 mg BID of Amantadine was compared with placebo in its affects on cognitive dysfunction 
and DRS and Neurobehavioral Rating Scale were used to evaluate that dysfunction.  
Voit – Amantadine & Cognitive Function  5 
 Key words used in the search engine Pub-Med included were “cognitive function”, 
“amantadine”, and “Traumatic Brain Injury”.  All articles used were English language 
randomized, double-blind, controlled cross-over studies from 1999 to 2012.  The articles were 
selected based on the importance of the outcomes to the patient.    
Outcomes Measured 
 The outcomes evaluated were POEMS (Patient Oriented Evidence that Matters).  For 
example, DRS and Neurobehavioral Rating scores were measured by rating improvements in 
several types of cognitive functioning.   The DRS (Disability Rating Scale) measured consistent 
command-following, object recognition, functional object use, intelligible verbalization, reliable 
yes-or-no communication, and sustained attention scores.  Scores were measured as a function of 
time, where disability was scored using a number scale; 7-13 being moderate-severe-to-severe, 
14-21 severe-to-extremely-severe, and 22-29 vegetative-state-to-extreme-vegetative-state.  The 
Neurobehavioral Rating scale involved tests in orientation, attention, memory, executive 
flexibility, and behavior as a function of time.  Functioning tests included consistent command-
following, reliable yes-or-no communication, and sustained attention. 
Table 1. Demographics of included studies 
Study Type # Pts Age 
Inclusion 
Criteria 
Exclusion 
Criteria W.D Interventions 
Giacano 
(2012) 
Double- 
Blind, 
RCT, 
Placebo-
controlled 
184 16-
65 
Patients who 
sustained a 
nonpenetrating 
traumatic brain 
injury who are 
currently in a 
vegetative state 
or a minimally 
conscious state 
Any patient 
with a CNS 
disability that 
predated the 
TBI 
3 Amantadine 
Meythaler 
(2002) 
Double-
Blind, 
RCT, 
Placebo-
35 16-
75 
Patients with a 
GCS of less than 
11, loss of 
consciousness 
Patients with 
penetrating 
TBI, prior 
experimental 
5 Amantadine 
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controlled immediately 
after a MVC, 
posttraumatic 
amnesia for at 
least 1 week  
drug use, 
history of 
cardiac 
disease 
Schneider 
(1999) 
Double-
Blind, 
RCT, 
Placebo-
Controlled 
10 18-
55 
Diagnosis of 
closed head 
injury, deficits 
in attention and 
concentration 
Pts with hx of 
cardiac 
disease, 
pregnant, 
psych history 
8 Amantadine 
 
Results 
 Three randomized controlled trials are presented in this review, using cognitive grading 
scales to track progress over time, with study participants being clinically diagnosed with 
Traumatic Brain Injury.   One trial was analyzed with intention to treat while the others as 
change in mean cognitive scores from baseline. 
 In the Galiano et al study, participants were given BID doses of 100 mg Amantadine for 
14 days, 150 mg at week three, and 200 mg at week four.2  A visually matched BID dose placebo 
was given to the control group.2  
 181 patients completed the trial.  At the end of the 4-week treatment interval, both the 
amantadine and control group had significant improvements in DRS scores, but the amantadine 
group had a faster rate of recovery.  Also, more patients in the amantadine group had positive 
DRS score outcomes and greater percentage of recovery at the end of the trial, as shown in Table 
1.2   
Table 2. Distribution of DRS scores after 4-week trial2 
Method Used Percentage of mod-severe-to-severe 
disability (95% CI) 
Percentage of 
severe-to-
extremely-severe 
(95% CI) 
Percentage of 
vegetative state to 
extreme vegetative 
(95% CI) 
      Amantadine 25.6 55.8 18.6 
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Placebo 16.8 51.6 31.6 
  
To analyze treatment effects, absolute benefit increase (ABI), relative benefit increase 
(RBI), and numbers needed to treat (NNT) values were used, shown below in Table 3.  RBI and 
ABI were calculated as 0.52% and 0.09%, respectively, while the number of patients needed to 
treat was 12.2 
Table 3. Treatment effects of randomized, placebo-controlled, double-blind crossover trial 
 
CER 
 
 
EER 
 
EER- CER 
CER 
(RBI) 
EER – CER 
(ABI) 
1/ABI 
(NNT) 
       0.168           0.256         0.523         0.09            12 
 
The Methayler et al trial included a study sample of 35 patients with diagnosed Traumatic 
Brain Injury.  Amantadine 200 mg QD was given to group one for 6 weeks, while group two was 
given a visually matched placebo.  For weeks 6-12 group one was given placebo and group two 
was given amantadine. 
All patients’ baseline DRS scores were taken and averaged as a whole in their respective 
groups.  After 6-week treatment with either placebo or amantadine, mean DRS scores were again 
taken, producing a new average for both groups.  New means were analyzed, using statistical 
procedures Wilcoxon signed-rank test and Mann-Whitney U test, shown below in Table 4.  After 
the initial 6 weeks, group one showed an improvement in DRS scores of 9.8 point (15.5 ± SD 4.5 
to 5.7 ± SD 4.2) improvement in DRS score, while showing a 0.15 point (5.7 ± SD 4.12 to 5.5 ± 
SD 4.6) during the second 6 weeks.3 
 Group two had a 9.4 point (21.7 ± 7.8 to 12.3 ± 9.9) improvement in DRS score and a 3.8 
point (12.3 ± 9.9 to 8.5 ± 9.0) improvement during weeks 6-12, while taking amantadine.  The 
Mann-Whitney U test showed a statistically different DRS point score at week zero, as 
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evidenced by P score of .0455 shown below, but there was still a statistically significant amount 
of change in favor of the amantadine group 2 at weeks 6 thru 12 (P=.2269).3 
Table 4. Wilcoxon Matched-Pair, Signed-Rank test results + Mann-Whitney U test.3 
 P-Values (Weeks 0-6) P-Values (Weeks 6-12) 
DRS Cognitive Function 
Assessment 
  
Group 1 0.0022 >0.05 
Group 2 0.0006 0.0099 
Mann-Whitney U test 0.045 0.2269 
 
In the review by Schneider et al, 10 participants diagnosed with TBI were separated into 
two groups.  Group one was started on 50 mg BID of amantadine and dose was increased every 3 
days to 150 mg.  After 2 weeks, patients were subjected to 2 weeks withdrawal, followed by 2 
weeks placebo.  Group two was given placebo for two weeks, followed by two weeks 
withdrawal, and then amantadine 50 mg BID with dose increased every 3 days up to 150 mg.4   
 Although only 2 subjects followed the trial to completion, the results were reported and 
analyzed.   Information was examined using repeated measures analysis of variance, which 
looked at test score results of five cognitive function variables: orientation, attention, memory, 
executive flexibility, behavior, and composite variable.  Scores in these areas were recorded over 
time and repeatedly compared to baseline scores.  This allowed researchers to compare results 
before and after testing.  Time by group interactions tests compared those scores over time with 
scores of the other group, indicating whether or not changes over time were different from 
amantadine group than placebo.  Results are shown below in Table 5.4 
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Table 5. Results of repeated measures of variance for effects of time4 
 Orientation Attention Memory Executive 
flexibility 
Behavior Composite 
variable 
Time p = 0.032 p =  0.047 p = 0.012 p = 0.001 p = 0.017 p = 0.003 
Time by 
group 
p = 0.849 p = 0.548 p = 0.425 p = 0.261 p = 0.852 p = 0.722 
Group p = 0.062 p =  0.325 p = 0.341 p = 0.732 p = 0.737 p = 0.405 
 
All scores improved over time between both groups one and two and there was no 
difference in rates of improvement.  This suggests that although cognitive function improved 
over time, the improvement was equal with and without amantadine.4 
Discussion 
 The Methayler and Giacano randomized control trials showed benefit in the use of 
amantadine following Traumatic Brain Injury.  These two trials showed an increased rate in 
cognitive function improvement, as measured by DRS, when compared to placebo.  The 
Schneider trial did not show a difference between the use of amantadine and placebo. 
 The Schneider trial offered conflicting information.  Although there were only two 
subjects who followed the trial to completion, initially only 10 subjects signed on, which is 
already too small a number to find significant effects.  Also, the rate of spontaneous recovery 
following a TBI is known to be high, which could have masked the positive effects of 
amantadine.4 
 The Methayler and Giacino studies both showed results consistent with acceleration of 
cognitive recovery in patients with acute losses of cognitive function following TBI.  Neither 
study demonstrated a benefit with early treatment compared to later and both seem to showed an 
Voit – Amantadine & Cognitive Function  10 
eventual “leveling-off” of DRS scores between amantadine and placebo groups.  However, both 
studies did demonstrate that patients improved more rapidly while on amantadine and 
improvement was sustained after follow-up.2,3   
Conclusion 
 Based on two of the trials addressed in this review, treatment with amantadine increases 
the rate of cognitive function improvement in patients with traumatic brain injury.  One study 
showed no benefit in the use of amantadine for TBI, but a small sample size hindered its validity.  
Overall, it can be inferred that amantadine does have a positive impact on the rate of cognitive 
recovery following TBI.   
 Although the Schneider study did not agree with the Methayler or Giacino, it provides an 
example of the importance of a large sample size.  It also demonstrates the difficulty in finding 
subjects for studies involving TBI.  Since decreased consciousness and cognitive function are 
central side effects of severe TBI, healthcare decision making for victims is often left in the 
hands of family members.  One can expect that some family members would be hesitant to 
subject their loved one to a pharmaceutical study of any kind during such a critical time.   
 Usage of amantadine in the realm of traumatic brain injury will likely continue to be 
explored and studied.  With proper education regarding its potential benefits and decreased side 
effects, more subjects for research will come.  This review provides significant patient-oriented 
evidence as well as incentive for further investigation. 
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